Status:
COMPLETED
A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis
Lead Sponsor:
Pfizer
Conditions:
Psoriatic Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to learn about the safety and effects of the study medicine for the potential treatment of Psoriatic Arthritis (PsA). Psoriatic Arthritis is a joint swelling disease that ...
Detailed Description
Tofacitinib is an oral Janus kinase (JAK) inhibitor approved in 2017 by the US Food and Drug Administration (FDA) for the treatment of adult patients with active PsA who have had an inadequate respons...
Eligibility Criteria
Inclusion
- PsA patients in CorEvitas initiating tofacitinib monotherapy or in combination with oral small molecules (eg methotrexate, leflunomide, sulfasalazine, apremilast) after 14 December 2017 (market approval of tofacitinib in the US) with no prior use of tofacitinib. Only the patient's first initiation after December 14, 2017 will be included in the analysis
- Have a 6 month follow-up visit (with ±3 month window)
Exclusion
- Patients taking tofacitinib in combination with any other bDMARD
Key Trial Info
Start Date :
November 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2023
Estimated Enrollment :
141 Patients enrolled
Trial Details
Trial ID
NCT05195814
Start Date
November 15 2021
End Date
October 31 2023
Last Update
March 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
New York, New York, United States, 10017